Citing Rise in Erroneous Test Requests, Aetna Investigates BRCA Testing Patterns in Two-Year Study | GenomeWeb

By Turna Ray

Following multiple accounts from payors about rising levels of inappropriate BRCA testing to gauge which women are at higher hereditary risk for breast and ovarian cancer, national insurer Aetna said last week that it will survey testing patterns among women treated in a community healthcare setting. The findings of the two-year study, which payors will surely be closely reviewing, could impact how BRACAnalysis, Myriad Genetics' flagship product, is covered by insurers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.